Skip to main content

Table 2 Changes in lipid measurements and atherogenic index of plasma from baseline to Month 12

From: Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

 

Pio + SU

n = 1709

Pio + Met

n = 1496

SU + Met

n = 1380

HDL-C

[108]

[96]

[85]

Change in means, %

6

6

3

Change in medians, %

7

9

2

Mean change, mmol/l

0.07

0.08

0.03

LDL-C

[128]

[125]

[127]

Change in means, %

-8

-8

-7

Change in medians, %

-5

-6

-5

Mean change, mmol/l

-0.32

-0.32

-0.26

Total-C

[70]

[70]

[72]

Change in means, %

-9

-9

-7

Change in medians, %

-7

-8

-5

Mean change, mmol/l

-0.51

-0.54

-0.39

Triglycerides

[53]

[54]

[39]

Change in means, %

-17

-19

-10

Change in medians, %

-15

-18

-9

Mean change, mmol/l

-0.35

-0.41

-0.21

AIP

[135]

[124]

[105]

Change in means, %

-18

-18

-10

Change in medians, %

-18

-18

-9

Mean change

-0.11

-0.12

-0.06

  1. Values within brackets indicate the number of patients with missing data for that variable. The numbers represent the percentage changes in the mean and median values, and the absolute mean change, from baseline to Month 12 (LOCF data).